Inotiv Inc (NOTV)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$0.01-26.00%
Close 2026-07-17 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Research Workspace
Put NOTV beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Primary pillar under pressure — Address Nasdaq delisting notice and regain listing compliance: Nasdaq compliance unresolved; Chapter 11 filed 2026-06-03.
View ThesisRevenue is growing steadily — about 6% over the past year.
View GrowthManagement screens weak on capital allocation, earnings delivery, the balance sheet, market reaction to earnings.
View ManagementThis stock is volatile — it swings about 6% on a typical day and fell roughly 100% in its worst 12-month stretch.
View RiskNOTV's growth depends on addressing its Nasdaq delisting notice and regaining compliance. Recent financial performance is weak, with a significant miss of -49% last quarter. It trades at a valuation that is below typical for its sector peers. The market is currently in a "Mania" cycle, which adds risk to its valuation. If NOTV misses again next quarter, the miss probability is 72%. Peer multiples imply a price about 0% below where it trades. Our read is provisional.
Trailing returns as of 2026-07-17. NOTV is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 1 analyst currently covering NOTV (as of Jun 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare NOTV with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| NOTV Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put NOTV next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Restructuring through Chapter 11 proceedings
Bankruptcy filing directly impacts restructuring efforts.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-17. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Manage financial obligations under Chapter 11
Debt reduction plan supports financial obligations management.
Threatens: Manage financial obligations under Chapter 11
Earnings miss indicates financial strain affecting obligations.